SCHEMBL1995046

SCHEMBL1995046

CCc1cccc(CC)c1NN

nearest known ligand 0.48

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
GABRA1 P14867 4/20 0.48
GABRB2 P47870 4/20 0.48
SCN5A Q14524 4/20 0.46
KCNH2 Q12809 2/20 0.46
CACNA1C Q13936 3/20 0.44
ALDH1A1 P00352 2/20 0.44
KDM4E B2RXH2 1/20 0.44
CLCN2 P51788 1/20 0.43
ALOX15 P16050 1/20 0.42
TSHR P16473 1/20 0.42
CYP2C19 P33261 1/20 0.42
HIF1A Q16665 1/20 0.42
TDP1 Q9NUW8 1/20 0.42
GAA P10253 1/20 0.41
MAPT P10636 1/20 0.41
NLRP3 Q96P20 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL20575649 0.98 GABRA1 (0.46) GABRA1GABRB2SCN5AKCNH2CACNA1C
Bromide SCHEMBL20984906 0.98 GABRA1 (0.46) GABRA1GABRB2SCN5AKCNH2CACNA1C
Sulfuric Acid SCHEMBL20984378 0.89 GABRA1 (0.45) GABRA1GABRB2SCN5AKCNH2CACNA1C
Phosphoric Acid SCHEMBL20984696 0.89 ALDH1A1 (0.50) GABRA1GABRB2SCN5AKCNH2CACNA1C
Oxalic Acid SCHEMBL20984894 0.89 CLCN2 (0.49) GABRA1GABRB2SCN5ACACNA1CALDH1A1
SCHEMBL28053372 0.89 GABRA1 (0.40) GABRA1GABRB2SCN5AKCNH2CACNA1C
SCHEMBL1994033 0.87 PTGS2 (0.49) GABRA1GABRB2ALDH1A1KDM4EALOX15
Nitric Acid SCHEMBL20984345 0.86 GABRA1 (0.42) GABRA1GABRB2SCN5AKCNH2CACNA1C
Hydrochloric Acid SCHEMBL19552211 0.85 PTGS2 (0.47) GABRA1GABRB2ALDH1A1KDM4EALOX15
SCHEMBL28429126 0.79 SCN5A (0.59) GABRA1GABRB2SCN5AKCNH2CACNA1C

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11773091-B2 6-5 fused rings as C5a inhibitors CHEMOCENTRYX, INC. (US) 2023-10-03 US disclosed
US-11773091-B2 6-5 fused rings as C5a inhibitors CHEMOCENTRYX, INC. (US) 2023-10-03 US disclosed
US-20230151002-A1 6-5 FUSED RINGS AS C5a INHIBITORS CHEMOCENTRYX, INC. 2023-05-18 US disclosed
CN-112409203-B Method for simultaneously synthesizing phenylhydrazine salt and pyruvic acid or glyoxylic acid 帕潘纳(北京)科技有限公司 2022-10-25 CN disclosed
US-20210300935-A1 PYRAZOLO-QUINAZOLINE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS KINASE INHIBITORS Nerviano Medical Sciences, S.R.L. (IT) 2021-09-30 US disclosed
CN-112409203-A Method for simultaneously synthesizing phenylhydrazine salt and pyruvic acid or glyoxylic acid 帕潘纳(北京)科技有限公司 2021-02-26 CN disclosed
WO-2019195159-A1 PRODRUGS OF FUSED-BICYCLIC C5aR ANTAGONISTS CHEMOCENTRYX, INC. (US) 2019-10-10 WO disclosed
US-20190194214-A1 PYRAZOLO-QUINAZOLINE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS KINASE INHIBITORS NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2019-06-27 US disclosed
US-10280176-B2 Pyrazolo-quinazoline derivatives, process for their preparation and their use as kinase inhibitors NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2019-05-07 US disclosed
CN-107663161-A A kind of continuous stream synthesis technique of phenylhydrazine salt and substituted benzene hydrazonium salt 上海惠和化德生物科技有限公司 2018-02-06 CN disclosed
US-20090216017-A1 PROCESS FOR PRODUCING BIARYL COMPOUND HAGIYA KOJI 2009-08-27 US disclosed
US-7554000-B2 Process for producing biaryl compound SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2009-06-30 US disclosed
US-20090099189-A1 CRTH2 Receptor Ligands For Medicinal Uses 7TM PHARMA A/S (DK) 2009-04-16 US disclosed
CN-1980664-A CRTH2 receptor ligands for therapeutic use 7TM PHARMA AS (DK) 2007-06-13 CN disclosed
EP-1758579-A1 CRTH2 RECEPTOR LIGANDS FOR MEDICINAL USES 7TM Pharma A/S (DK) 2007-03-07 EP disclosed
WO-2005115382-A1 CRTH2 RECEPTOR LIGANDS FOR MEDICINAL USES 7TM PHARMA A/S (DK) 2005-12-08 WO disclosed
US-20050096471-A1 Process for producing biaryl compound SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2005-05-05 US disclosed
EP-1473286-A1 PROCESS FOR PRODUCING BIARYL COMPOUND Sumitomo Chemical Company, Limited (JP) 2004-11-03 EP disclosed
US-3979412-A Process for producing 3-anilino-5-pyrazolones FUJI PHOTO FILM CO., LTD. (JA) 1976-09-07 US disclosed
US-3933874-A Method for preparing of β-anilino-β-hydrazinoacrylates FUJI PHOTO FILM CO., LTD. (JA) 1976-01-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210300935-A1 PYRAZOLO-QUINAZOLINE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS KINASE INHIBITORS MAP3K5, MAP3K9, MAP4K2 GABRA1 4030/4885GABRB2 4195/4885SCN5A 951/4885
US-20230151002-A1 6-5 FUSED RINGS AS C5a INHIBITORS C5AR1, C5AR2, C3AR1 GABRA1 1655/4885GABRB2 2375/4885SCN5A 1028/4885
US-20190194214-A1 PYRAZOLO-QUINAZOLINE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS KINASE INHIBITORS MAP3K5, MAP3K9, MAP4K2 GABRA1 4001/4885GABRB2 4158/4885SCN5A 938/4885
US-10280176-B2 Pyrazolo-quinazoline derivatives, process for their preparation and their use as kinase inhibitors MAP3K5, MAP3K9, MAP4K2 GABRA1 4001/4885GABRB2 4158/4885SCN5A 938/4885
US-11773091-B2 6-5 fused rings as C5a inhibitors C5AR1, C5AR2, C3AR1 GABRA1 1655/4885GABRB2 2375/4885SCN5A 1028/4885
US-20090216017-A1 PROCESS FOR PRODUCING BIARYL COMPOUND PPOX, CAT, TYR GABRA1 2373/4885GABRB2 1898/4885SCN5A 3210/4885
US-20090099189-A1 CRTH2 Receptor Ligands For Medicinal Uses HRH1, HRH2, HRH3 GABRA1 853/4885GABRB2 1052/4885SCN5A 3850/4885
US-20050096471-A1 Process for producing biaryl compound PPOX, CAT, TYR GABRA1 2373/4885GABRB2 1898/4885SCN5A 3210/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.